Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Change in Receivables (2017 - 2024)

Protagonist Therapeutics (PTGX) has disclosed Change in Receivables for 8 consecutive years, with $165.0 million as the latest value for Q4 2024.

  • Quarterly Change in Receivables rose 1550.0% to $165.0 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $155.0 million through Dec 2024, up 1451.55% year-over-year, with the annual reading at $155.0 million for FY2024, 1451.55% up from the prior year.
  • Change in Receivables hit $165.0 million in Q4 2024 for Protagonist Therapeutics, up from -$43000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $290.0 million in Q1 2024 to a low of -$300.0 million in Q2 2024.
  • Historically, Change in Receivables has averaged $7.9 million across 5 years, with a median of -$41000.0 in 2023.
  • Biggest YoY gain for Change in Receivables was 707321.95% in 2024; the steepest drop was 2499900.0% in 2024.
  • Year by year, Change in Receivables stood at -$363000.0 in 2020, then crashed by 195.32% to -$1.1 million in 2021, then soared by 89.27% to -$115000.0 in 2022, then soared by 8795.65% to $10.0 million in 2023, then surged by 1550.0% to $165.0 million in 2024.
  • Business Quant data shows Change in Receivables for PTGX at $165.0 million in Q4 2024, -$43000.0 in Q3 2024, and -$300.0 million in Q2 2024.